Boston Scientific (NYSE:BSX) Sets New 12-Month Low Following Analyst Downgrade

Boston Scientific Corporation (NYSE:BSX) shares reached a new 52-week low during mid-day trading on Wednesday after Needham & Company LLC lowered their price target on the stock from $57.00 to $48.00. Needham & Company LLC currently has a buy rating on the stock. Boston Scientific traded as low as $39.57 and last traded at $43.0990, with a volume of 35,453,115 shares. The stock had previously closed at $45.06.

BSX has been the topic of several other research reports. Robert W. Baird set a $56.00 target price on shares of Boston Scientific in a research report on Thursday, July 30th. BTIG Research decreased their price target on Boston Scientific from $60.00 to $56.00 and set a “buy” rating for the company in a research report on Wednesday, September 9th. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a report on Sunday, August 2nd. TD Cowen reissued a “buy” rating on shares of Boston Scientific in a research report on Tuesday, October 20th. Finally, Leerink Partners reduced their price objective on Boston Scientific from $60.00 to $55.00 in a research note on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $65.63.

Insider Buying and Selling at Boston Scientific

In related news, Director Edward Ludwig purchased 5,000 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were purchased at an average cost of $45.48 per share, for a total transaction of $227,400.00. Following the completion of the transaction, the director directly owned 30,359 shares in the company, valued at approximately $1,380,727.32. This represents a 19.72% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Michael Mahoney purchased 186,240 shares of the stock in a transaction dated Monday, August 3rd. The stock was purchased at an average cost of $48.33 per share, for a total transaction of $9,000,979.20. Following the completion of the acquisition, the chief executive officer owned 1,590,024 shares of the company’s stock, valued at approximately $76,845,859.92. This represents a 13.27% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 194,522 shares of company stock valued at $9,385,210 in the last quarter. 0.34% of the stock is currently owned by corporate insiders.

More Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Boston Scientific reported third-quarter adjusted earnings of $0.73 per share, slightly above the $0.72 consensus estimate, while revenue of $5.138 billion also exceeded expectations of approximately $5.06 billion. Boston Scientific third-quarter earnings report
• Positive Sentiment: Management highlighted longer-term potential, targeting a business-cycle trough in 2027 and expansion toward 2030. The company also began enrollment in its Elite AF clinical trial and received FDA clearances for StoneSmart technologies and an expanded SEISMIQ catheter offering. Boston Scientific third-quarter results announcement
• Neutral Sentiment: Third-quarter reported sales increased 1.5% year over year to $5.138 billion, but adjusted EPS declined from $0.75 to $0.73 and GAAP EPS fell from $0.51 to $0.40. Cardiovascular sales rose 1.9%, while MedSurg sales grew only 0.6%; regional performance was mixed.
• Negative Sentiment: Boston Scientific again reduced its fiscal-year 2026 outlook after a cybersecurity incident disrupted operations and weighed on demand. Management now expects approximately 4.25% reported sales growth for the year and forecasts fourth-quarter reported and organic sales declines of 1% to 3%. Boston Scientific outlook and cybersecurity report
• Negative Sentiment: The cybersecurity fallout, other operating headwinds and lower guidance overshadowed the earnings and revenue beats. The stock was trading near its 52-week low and below both its 50-day and 200-day moving averages, reflecting continued investor concern about near-term execution and growth.

Institutional Investors Weigh In On Boston Scientific

Institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. bought a new stake in shares of Boston Scientific during the 2nd quarter valued at about $5,534,781,000. Primecap Management Co. CA purchased a new position in shares of Boston Scientific during the second quarter worth about $2,156,233,000. Jupiter Topco LLC bought a new position in shares of Boston Scientific in the second quarter worth approximately $803,357,000. Janus Henderson Group PLC raised its stake in Boston Scientific by 31.0% in the first quarter. Janus Henderson Group PLC now owns 16,497,366 shares of the medical equipment provider’s stock valued at $1,035,202,000 after purchasing an additional 3,907,981 shares in the last quarter. Finally, Amundi lifted its position in Boston Scientific by 1.2% during the second quarter. Amundi now owns 14,296,121 shares of the medical equipment provider’s stock valued at $610,158,000 after purchasing an additional 173,208 shares during the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Trading Down 3.9%

The company has a quick ratio of 0.74, a current ratio of 1.24 and a debt-to-equity ratio of 0.43. The firm has a market capitalization of $62.76 billion, a P/E ratio of 17.54, a price-to-earnings-growth ratio of 1.10 and a beta of 0.58. The firm’s 50-day simple moving average is $45.29 and its 200-day simple moving average is $57.71.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of $0.72 by $0.01. The firm had revenue of $5.14 billion for the quarter, compared to analyst estimates of $5.06 billion. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.75 EPS. Analysts anticipate that Boston Scientific Corporation will post 3.21 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation is a medical technology company that develops, manufactures and markets devices used to diagnose and treat a broad range of complex medical conditions. Founded in 1979 and headquartered in Marlborough, Massachusetts, the company serves healthcare providers and patients worldwide.

Its products support minimally invasive procedures in areas including interventional cardiology, peripheral interventions, electrophysiology, endoscopy, urology and neuromodulation.